Research ExplorerPublicationsEfficacy of rocatinlimab for moderate-to-severe atopic derma...

Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis - Authors' reply

Standard

Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis - Authors' reply. / Guttman-Yassky, Emma; Simpson, Eric L; Reich, Kristian; Kabashima, Kenji; Igawa, Ken; Suzuki, Tetsuya; Mano, Hirotaka; Matsui, Takeshi; Esfandiari, Ehsanollah; Furue, Masutaka.

In: LANCET, Vol. 402, No. 10415, 18.11.2023, p. 1834.

Research output: SCORING: Contribution to journal › Comment/debate › Research

Harvard

Guttman-Yassky, E, Simpson, EL, Reich, K, Kabashima, K, Igawa, K, Suzuki, T, Mano, H, Matsui, T, Esfandiari, E & Furue, M 2023, 'Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis - Authors' reply', LANCET, vol. 402, no. 10415, pp. 1834. https://doi.org/10.1016/S0140-6736(23)01618-5

APA

Guttman-Yassky, E., Simpson, E. L., Reich, K., Kabashima, K., Igawa, K., Suzuki, T., Mano, H., Matsui, T., Esfandiari, E., & Furue, M. (2023). Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis - Authors' reply. LANCET, 402(10415), 1834. https://doi.org/10.1016/S0140-6736(23)01618-5

Vancouver

Guttman-Yassky E, Simpson EL, Reich K, Kabashima K, Igawa K, Suzuki T et al. Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis - Authors' reply. LANCET. 2023 Nov 18;402(10415):1834. https://doi.org/10.1016/S0140-6736(23)01618-5

Bibtex

@article{807e44d6cfa34d13ac74010d87c74f98,
title = "Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis - Authors' reply",
keywords = "Humans, Dermatitis, Atopic/drug therapy, Severity of Illness Index, Treatment Outcome, Double-Blind Method",
author = "Emma Guttman-Yassky and Simpson, {Eric L} and Kristian Reich and Kenji Kabashima and Ken Igawa and Tetsuya Suzuki and Hirotaka Mano and Takeshi Matsui and Ehsanollah Esfandiari and Masutaka Furue",
year = "2023",
month = nov,
day = "18",
doi = "10.1016/S0140-6736(23)01618-5",
language = "English",
volume = "402",
pages = "1834",
journal = "LANCET",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "10415",

}

RIS

TY - JOUR

T1 - Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis - Authors' reply

AU - Guttman-Yassky, Emma

AU - Simpson, Eric L

AU - Reich, Kristian

AU - Kabashima, Kenji

AU - Igawa, Ken

AU - Suzuki, Tetsuya

AU - Mano, Hirotaka

AU - Matsui, Takeshi

AU - Esfandiari, Ehsanollah

AU - Furue, Masutaka

PY - 2023/11/18

Y1 - 2023/11/18

KW - Humans

KW - Dermatitis, Atopic/drug therapy

KW - Severity of Illness Index

KW - Treatment Outcome

KW - Double-Blind Method

U2 - 10.1016/S0140-6736(23)01618-5

DO - 10.1016/S0140-6736(23)01618-5

M3 - Comment/debate

C2 - 37980090

VL - 402

SP - 1834

JO - LANCET

JF - LANCET

SN - 0140-6736

IS - 10415

ER -